Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

C. Tarella
, M. Zanni
, M. Di Nicola
, C. Patti
, R. Calvi
, A. Pescarollo
, V. Zoli
, A. Fornari
, D. Novero
, A. Cabras
, M. Stella
, A. Comino
, D. Remotti
, M. Ponzoni
, D. Caracciolo
, M. Ladetto
, M. Magni
, L. Devizzi
, R. Rosato
, M. Boccadoro

M. Bregni, P. Corradini, A. Gallamini, I. Majolino, S. Mirto, A. M. Gianni

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Fingerprint

Entra nei temi di ricerca di 'Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)'. Insieme formano una fingerprint unica.

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

Fingerprint

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Immunology and Microbiology